Centogene N.V. (CNTGF) - Total Liabilities
Based on the latest financial reports, Centogene N.V. (CNTGF) has total liabilities worth $102.44 Million USD as of December 2023. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Centogene N.V. (CNTGF) equity growth momentum to track the company's year-over-year net asset growth rate.
Centogene N.V. - Total Liabilities Trend (2020–2023)
This chart illustrates how Centogene N.V.'s total liabilities have evolved over time, based on quarterly financial data. See Centogene N.V. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Centogene N.V. Competitors by Total Liabilities
The table below lists competitors of Centogene N.V. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
USA | $4.78 Million |
|
Atlantic Sapphire As
OL:ASA
|
Norway | Nkr123.89 Million |
|
Parkd Ltd
AU:PKD
|
Australia | AU$1.49 Million |
|
Destiny Media Technologies Inc
V:DSY
|
Canada | CA$731.82K |
|
Omnia Metals Group Ltd
AU:OM1
|
Australia | AU$276.32K |
|
Property Franchise Group PLC
LSE:TPFG
|
UK | GBX51.32 Million |
|
Conifex Timber Inc
TO:CFF
|
Canada | CA$143.50 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Centogene N.V.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Centogene N.V..
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.02 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Centogene N.V.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Centogene N.V. (2020–2023)
The table below shows the annual total liabilities of Centogene N.V. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $102.44 Million | +19.95% |
| 2022-12-31 | $85.40 Million | +33.69% |
| 2021-12-31 | $63.88 Million | -24.84% |
| 2020-12-31 | $84.99 Million | -- |
About Centogene N.V.
Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA … Read more